The need for uniform and coordinated practices involving centrally manufactured cell therapies
Abstract Cellular therapies have become an important part of clinical care. The treatment of patients with cell therapies often involves the collection of autologous cells at the medical center treating the patient, the shipment of these cells to a centralized manufacturing site, and the return of t...
Main Authors: | David Stroncek, Anh Dinh, Herleen Rai, Nan Zhang, Rob Somerville, Sandhya Panch |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-04-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-022-03385-9 |
Similar Items
-
Expanding the reach of commercial cell therapies requires changes at medical centers
by: David F. Stroncek, et al.
Published: (2024-02-01) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
by: Adriana Seber, et al.
Published: (2021-11-01) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
by: Alvaro J. Alencar, et al.
Published: (2021-11-01) -
Cell, gene and molecular therapy : new concepts /
by: 388760 Viroj Wiwanitkit
Published: (2009) -
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules
by: Jianjian Jin, et al.
Published: (2018-01-01)